X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (38363) 38363
Publication (3343) 3343
Newsletter (646) 646
Newspaper Article (629) 629
Book Review (335) 335
Book Chapter (211) 211
Dissertation (48) 48
Book / eBook (35) 35
Conference Proceeding (34) 34
Magazine Article (32) 32
Trade Publication Article (21) 21
Web Resource (11) 11
Reference (10) 10
Data Set (7) 7
Report (2) 2
Government Document (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (21708) 21708
male (16184) 16184
humans (14181) 14181
index medicus (13321) 13321
rats (10599) 10599
adenosine (10368) 10368
female (8454) 8454
adenosine triphosphate - metabolism (5544) 5544
mice (5254) 5254
pharmacology & pharmacy (4947) 4947
neurosciences (4395) 4395
middle aged (3767) 3767
cardiac & cardiovascular systems (3580) 3580
dose-response relationship, drug (3466) 3466
adult (3230) 3230
rats, sprague-dawley (3043) 3043
adenosine triphosphatase (2974) 2974
adenosine - pharmacology (2889) 2889
physiology (2873) 2873
time factors (2867) 2867
biochemistry & molecular biology (2745) 2745
research (2694) 2694
rats, wistar (2677) 2677
aged (2591) 2591
analysis (2591) 2591
adenosine triphosphate (2525) 2525
in vitro techniques (2471) 2471
physiological aspects (2461) 2461
cell biology (2345) 2345
proteins (2226) 2226
metabolism (2142) 2142
adenosine - analogs & derivatives (2079) 2079
rodents (2046) 2046
atp (2042) 2042
disease models, animal (2036) 2036
oxidative stress (1936) 1936
adenosine - administration & dosage (1909) 1909
ischemia (1891) 1891
activation (1880) 1880
inhibition (1872) 1872
apoptosis (1828) 1828
brain (1826) 1826
adenosine triphosphate - pharmacology (1794) 1794
expression (1707) 1707
article (1641) 1641
cells, cultured (1636) 1636
inflammation (1635) 1635
medicine (1583) 1583
adenosine triphosphatases - metabolism (1581) 1581
health aspects (1574) 1574
research article (1542) 1542
platelet aggregation - drug effects (1523) 1523
cells (1502) 1502
peripheral vascular disease (1464) 1464
adenosine diphosphate - pharmacology (1458) 1458
receptors (1444) 1444
rat (1442) 1442
phosphorylation (1411) 1411
dogs (1403) 1403
care and treatment (1402) 1402
kinases (1367) 1367
myocardium - metabolism (1346) 1346
gene expression (1334) 1334
heart (1331) 1331
enzymes (1325) 1325
signal transduction (1323) 1323
rats, inbred strains (1317) 1317
rabbits (1316) 1316
surgery (1313) 1313
medicine, research & experimental (1308) 1308
treatment outcome (1304) 1304
caffeine (1289) 1289
hematology (1289) 1289
mice, inbred c57bl (1281) 1281
calcium - metabolism (1265) 1265
adenosine - metabolism (1260) 1260
cardiology (1257) 1257
nitric oxide (1253) 1253
mitochondria (1246) 1246
endocrinology & metabolism (1244) 1244
multidisciplinary sciences (1236) 1236
oncology (1233) 1233
cancer (1194) 1194
kinetics (1157) 1157
liver - metabolism (1144) 1144
immunology (1138) 1138
medicine & public health (1104) 1104
blood pressure - drug effects (1080) 1080
neurons (1080) 1080
studies (1078) 1078
receptor (1075) 1075
liver (1042) 1042
science (1032) 1032
muscle proteins (1015) 1015
pharmacology (1015) 1015
nitric-oxide (1001) 1001
adenosine receptors (988) 988
brain - metabolism (987) 987
neurology (983) 983
biochemistry (981) 981
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (26) 26
Earth Sciences (Noranda) - Stacks (2) 2
UTL at Downsview - May be requested (2) 2
UofT at Mississauga - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Online Resources - Online (1) 1
Scarborough Hospital - General (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (38879) 38879
Russian (293) 293
German (177) 177
Japanese (160) 160
French (80) 80
Chinese (59) 59
Spanish (56) 56
Italian (52) 52
Polish (36) 36
Ukrainian (29) 29
Portuguese (16) 16
Korean (13) 13
Czech (9) 9
Slovak (9) 9
Turkish (9) 9
Hungarian (8) 8
Swedish (7) 7
Bulgarian (2) 2
Croatian (2) 2
Danish (2) 2
Persian (2) 2
Serbian (2) 2
Afrikaans (1) 1
Dutch (1) 1
Finnish (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The Lancet, ISSN 0140-6736, 2006, Volume 368, Issue 9548, pp. 1696 - 1705
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying, and... 
MEDICINE, GENERAL & INTERNAL | IN-VITRO | METFORMIN-TREATED PATIENTS | HEALTHY-SUBJECTS | 2ND-PHASE INSULIN-SECRETION | IMPROVES GLYCEMIC CONTROL | BETA-CELL APOPTOSIS | IV INHIBITOR | 7-36 AMIDE | IMPROVED GLUCOSE-TOLERANCE | EXENATIDE SYNTHETIC EXENDIN-4 | Triazoles - administration & dosage | Triazoles - adverse effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Pyrazines - administration & dosage | Glucagon-Like Peptide 1 - biosynthesis | Dipeptidyl Peptidase 4 | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Adenosine Deaminase Inhibitors | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Pyrrolidines | Venoms - administration & dosage | Nitriles | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Glucagon-Like Peptide 1 - classification | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glycoproteins - antagonists & inhibitors | Clinical Trials as Topic | Glucagon-Like Peptide-1 Receptor | Dipeptidyl-Peptidase IV Inhibitors | Pyrazines - adverse effects | Venoms - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Diagnosis | Glucagon | Analysis | Dosage and administration | Research | Protease inhibitors | Drug therapy | Proteins | Diabetes | Kinases | Insulin | Rodents
Journal Article
Thrombosis Research, ISSN 0049-3848, 01/2017, Volume 149, pp. 88 - 94
Journal Article
Molecular Neurobiology, ISSN 0893-7648, 8/2018, Volume 55, Issue 8, pp. 7038 - 7048
Journal Article
European Heart Journal, ISSN 0195-668X, 2017, Volume 38, Issue 41, pp. 3070 - 3078
Journal Article
Journal of the American Chemical Society, ISSN 0002-7863, 04/2003, Volume 125, Issue 15, pp. 4451 - 4459
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2011, Volume 58, Issue 22, pp. 2263 - 2269
Chronic kidney disease (CKD) is prevalent and affects an ever-increasing proportion of patients presenting with acute coronary syndrome (ACS). Patients with... 
Cardiovascular | Internal Medicine | non–ST-segment elevation myocardial infarction | chronic kidney disease | bleeding | ST-segment elevation myocardial infarction | unstable angina | acute coronary syndrome(s) | antiplatelet | antithrombotic | nonST-segment elevation myocardial infarction | CARDIAC & CARDIOVASCULAR SYSTEMS | WAVE MYOCARDIAL-INFARCTION | HIGH-RISK PATIENTS | GLYCOPROTEIN IIB/IIIA INHIBITORS | non-ST-segment elevation myocardial infarction | MOLECULAR-WEIGHT HEPARIN | PLATELET INHIBITION | DOUBLE-BLIND | ST-SEGMENT ELEVATION | STAGE RENAL-DISEASE | UNFRACTIONATED HEPARIN | ARTERY-DISEASE | Piperazines - administration & dosage | Prasugrel Hydrochloride | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Heparin - administration & dosage | Thiophenes - administration & dosage | Recombinant Proteins - adverse effects | Heparin - adverse effects | Hirudins - administration & dosage | Aspirin - administration & dosage | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Acute Coronary Syndrome - complications | Aspirin - adverse effects | Adenosine - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Polysaccharides - administration & dosage | Kidney Diseases - complications | Platelet Aggregation Inhibitors - adverse effects | Peptide Fragments - administration & dosage | Polysaccharides - adverse effects | Clinical Trials as Topic | Uremia - complications | Adenosine - administration & dosage | Piperazines - adverse effects | Recombinant Proteins - administration & dosage | Ticlopidine - analogs & derivatives | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Hirudins - adverse effects | Fibrinolytic Agents - administration & dosage | Peptide Fragments - adverse effects | Hemorrhage - chemically induced | Chronic Disease | Care and treatment | Chronic kidney failure | Cardiac patients | Cardiology | Coronary heart disease | Health aspects | Cardiovascular agents | Medical colleges | Mortality | Heart attacks | Drug therapy | Acute coronary syndromes | Coronary vessels
Journal Article
Journal Article
American Journal of Physiology - Regulatory, Integrative and Comparative Physiology, ISSN 0363-6119, 10/2009, Volume 297, Issue 4, pp. 1095 - 1102
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 19, pp. 1791 - 1800
Patients with myocardial infarction 1 to 3 years previously were assigned to ticagrelor, 90 or 60 mg twice daily, or to placebo, in addition to low-dose... 
MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | CLOPIDOGREL | MANAGEMENT | ESC GUIDELINES | AMERICAN-COLLEGE | PREVENTION | ASSOCIATION TASK-FORCE | ACUTE CORONARY SYNDROMES | PRASUGREL | ASPIRIN | Purinergic P2Y Receptor Antagonists - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Risk | Secondary Prevention | Adenosine - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Myocardial Infarction - drug therapy | Adenosine - adverse effects | Adenosine - analogs & derivatives | Intracranial Hemorrhages - chemically induced | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Aged | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Dose-response relationship (Biochemistry) | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Dosage and administration | Ticagrelor | Heart attack | Risk factors | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Heart attacks | Hemorrhage | Long term | Patients | Thrombolysis | Bleeding | Blood platelets | Antagonist drugs | Cardiovascular diseases | Drug therapy | Life Sciences | Human health and pathology
Journal Article